# An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

> **NCT01085266** · PHASE3 · TERMINATED · sponsor: **Medivation, Inc.** · enrollment: 362 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** Dimebon (latrepirdine)

## Key facts

- **NCT ID:** NCT01085266
- **Lead sponsor:** Medivation, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-06
- **Final completion:** —
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085266, "An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01085266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*